Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Diane Matsumoto

Pediatrics Phoenix, AZ Medical Doctor

NPI 1215039227 CMS profile 236131

16611 S 40Th St, Ste 160, Phoenix, AZ 85048

Open in the dashboard

General payments

$4,996

274 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Diane Matsumoto of Phoenix, AZ is reported in the CMS Open Payments database as having received $4,996 across 274 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Pediatrics profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $851 42
2024 General $903 43
2023 General $898 43
2022 General $765 46
2021 General $737 43
2020 General $406 28
2019 General $437 29

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Diane Matsumoto
  • Pediatrics median
  • Middle half of Pediatrics
  • National median

In program year 2025, general payments to Diane Matsumoto were reported at $851. Among 22,296 Pediatrics profiles paid that year, the median was $97 and the middle half received between $37 and $210.

Show as a table
Year Diane Matsumoto Pediatrics median Middle half National median
2019 $437 $86 $31–$183 $163
2020 $406 $49 $22–$110 $114
2021 $737 $68 $27–$158 $132
2022 $765 $77 $30–$173 $149
2023 $898 $88 $33–$190 $160
2024 $903 $94 $34–$206 $164
2025 $851 $97 $37–$210 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Merck Sharp & Dohme Corporation $578 31 payments
  2. Tris Pharma Inc $553 45 payments
  3. GlaxoSmithKline, LLC. $467 26 payments
  4. Corium, Inc. $438 28 payments
  5. Pfizer Inc. $398 19 payments
  6. Supernus Pharmaceuticals, Inc. $344 15 payments
  7. kaleo, Inc. $231 8 payments
  8. Cranial Technologies, Inc $176 11 payments
  9. Genentech USA, Inc. $164 10 payments
  10. ACADIA Pharmaceuticals Inc $140 6 payments
  11. Other $1,505 75 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,978 273 payments
  2. Education $18 1 payment
Products named General payments · program years 2019–2025
  1. GARDASIL 9 $500 27 payments
  2. BEXSERO $467 26 payments
  3. Azstarys $438 28 payments
  4. ROTATEQ $396 22 payments
  5. VAXNEUVANCE $362 18 payments
  6. COMIRNATY $351 16 payments
  7. VAXELIS $331 18 payments
  8. PREVNAR 20 $311 14 payments
  9. M-M-R II $235 12 payments
  10. AUVI-Q $231 8 payments
  11. Other $4,215 230 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

274 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record